ReviewSexually transmitted infections2007
Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance.
Review in Sexually transmitted infections, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Vaccination Schedule and Age Influence Impaired Responsiveness to Hepatitis B Vaccination: A Randomized Trial in Central Asia.Pathogens (Basel, Switzerland) · 2024Trial
- Trial
- Hepatitis A/B vaccine completion among homeless adults with history of incarceration.Journal of forensic nursing · 2012Trial
- Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine.Clinical and vaccine immunology : CVI · 2011Trial
- Predictors of HAV/HBV vaccination completion among methadone maintenance clients.Research in nursing & health · 2010Trial
- Feasibility of completing an accelerated vaccine series for homeless adults.Journal of viral hepatitis · 2009Trial
- Epidemiological and molecular characterization of HBV and HCV infections in HIV-1-infected inmate population in Italy: a 2017-2019 multicenter cross-sectional study.Scientific reports · 2023Article
- Article
- Two-year immune effect differences between the 0-1-2-month and 0-1-6-month HBV vaccination schedule in adults.BMC infectious diseases · 2022Article
- Viral Hepatitis - The Road Traveled and the Journey Remaining.Hepatic medicine : evidence and research · 2022Review
- Undetectable Anti-HBs Antibodies: Need of a Booster Dose for HIV-1-Infected Individuals.Vaccines · 2021Review
- Letter to the editor: female sex workers and HPV vaccine.Human vaccines & immunotherapeutics · 2020Article
- Hepatitis B vaccination and immunotherapies: an update.Clinical and experimental vaccine research · 2020Review
- Short-term immunogenicity of standard and accelerated hepatitis B virus vaccination schedules in healthy adults: a comparative field study in China.Bioscience reports · 2018Article
- Emerging Trends in Epidemiology of Hepatitis B Virus Infection.Journal of clinical and translational hepatology · 2017Review
- Shortened Intervals during Heterologous Boosting Preserve Memory CD8 T Cell Function but Compromise Longevity.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- The rhesus macaque pediatric SIV infection model - a valuable tool in understanding infant HIV-1 pathogenesis and for designing pediatric HIV-1 prevention strategies.Current HIV research · 2009Review
- Comparison of Serological Immune Response to Hepatitis B Vaccine Following Rapid or Standard Regimen in People Who Inject Drugs.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVaccination is an important tool in hepatitis B prevention. However, several vaccine doses are required to induce long-term protection. Several at-risk groups have difficulties in adhering to the standard vaccination schedule.
objectivesThis paper aims to review the use of accelerated hepatitis B vaccination schedules, in terms of immunogenicity and compliance.
resultsAccelerated schedules (0.1.2.12 months) or super-accelerated schedules (0.7.21.360 days) have been shown to result in higher proportions of healthy vaccinees reaching anti-HBs antibody levels >or=10 IU/l more rapidly. A fourth completing dose is required to lift antibody levels to an equal height, as does a standard (0.1.6 months) schedule. Accelerated schedules do also increase the uptake of hepatitis B vaccine, that is the proportion of vaccinees who receive three doses. However, completing the schedule with a fourth dose is usually more difficult than completing a standard 0.1.6-month schedule. Several additional tools can help to increase the compliance (eg, reminder systems, outreach services and incentive schemes).
conclusionFor rapid seroconversion and almost immediate protection in the short term, a (super)accelerated schedule could be used in at-risk groups. As long-term protection data with these (super) accelerated schedules have not been documented yet, a fourth dose at month 12 is still required. A shortened schedule (0.1.4 months) might be an alternative worth considering compared with the standard 0.1.6, as it convenes to internationally accepted minimum dose intervals and offers earlier protection. There is a clear need to study the long-term protection and effectiveness of the primary part of (super)accelerated schedules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.